𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hyposmia and executive dysfunction as predictors of future Parkinson's disease: A prospective study

✍ Scribed by Mirthe M. Ponsen; Diederick Stoffers; Jos W.R. Twisk; Erik Ch. Wolters; Henk W. Berendse


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
69 KB
Volume
24
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Olfactory deficits and executive dysfunction are early and common symptoms in Parkinson's disease (PD). Previous studies have shown that hyposmia can be a first sign of PD. The aim of the present study was to determine which of three olfactory tests and two selected tests of executive function would be the best predictor of future PD over a 5 year period. In a cohort of 361 nonparkinsonian, nondemented first‐degree relatives of PD patients, in whom alternative causes of olfactory dysfunction were excluded, we measured baseline performance on three olfactory and two executive function tasks. Five years from baseline, clinical neurological evaluation and/or a screening questionnaire, sensitive to the presence of Parkinsonism, were used to detect individuals developing clinical PD. Our results show that in first degree relatives of PD patients worse performance on each of three olfactory processing tasks was associated with an increased risk of developing PD within 5 years, whereas performance on selected tests of executive dysfunction was not associated with an increased risk of developing PD. Interestingly, impaired odor discrimination was the best predictor for future PD. Β© 2009 Movement Disorder Society


πŸ“œ SIMILAR VOLUMES


Atomoxetine for the treatment of executi
✍ Laura Marsh; Kevin Biglan; Melissa Gerstenhaber; James R. Williams πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 321 KB πŸ‘ 1 views

## Abstract Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson's disease (PD). Few studies have examined treatments. Given the role of noradrenergic pathology in ED, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention defi

Rate of clinical progression in Parkinso
✍ Anette Schrag; Richard Dodel; Annika Spottke; Bernhard Bornschein; Uwe Siebert; πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 79 KB πŸ‘ 1 views

## Abstract Few prospective data on the clinical progression of Parkinson's disease (PD) in patient groups outside treatment trials in selected patients are available, and controversy exists on the rate of clinical disease progression with advancing disease. In this study, we investigated the rate

Prospective study of phobic anxiety and
✍ Marc G. Weisskopf; Honglei Chen; Michael A. Schwarzschild; Ichiro Kawachi; Alber πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 67 KB πŸ‘ 1 views

## Abstract Anxiety disorders are common in Parkinson's disease (PD). However, the risk of PD among people with anxiety has not been examined in a prospective cohort study. We examined this relation prospectively within the Health Professionals Follow‐Up Study, a cohort of US male health profession